1
|
Zhang J, Lin R, Li Y, Wang J, Ding H, Fang P, Huang Y, Shi J, Gao J, Zhang T. A large-scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation. Biotechnol J 2024; 19:e2300174. [PMID: 38403399 DOI: 10.1002/biot.202300174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 01/04/2024] [Accepted: 01/05/2024] [Indexed: 02/27/2024]
Abstract
Mesenchymal stem cells (MSCs) and their produced exosomes have demonstrated inherent capabilities of inflammation-guided targeting and inflammatory modulation, inspiring their potential applications as biologic agents for inflammatory treatments. However, the clinical applications of stem cell therapies are currently restricted by several challenges, and one of them is the mass production of stem cells to satisfy the therapeutic demands in the clinical bench. Herein, a production of human amnion-derived MSCs (hMSCs) at a scale of over 1 × 109 cells per batch was reported using a three-dimensional (3D) culture technology based on microcarriers coupled with a spinner bioreactor system. The present study revealed that this large-scale production technology improved the inflammation-guided migration and the inflammatory suppression of hMSCs, without altering their major properties as stem cells. Moreover, these large-scale produced hMSCs showed an efficient treatment against the lipopolysaccharide (LPS)-induced lung inflammation in mice models. Notably, exosomes collected from these large-scale produced hMSCs were observed to inherit the efficient inflammatory suppression capability of hMSCs. The present study showed that 3D culture technology using microcarriers coupled with a spinner bioreactor system can be a promising strategy for the large-scale expansion of hMSCs with improved anti-inflammation capability, as well as their secreted exosomes.
Collapse
Affiliation(s)
- Jinsong Zhang
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Ruyi Lin
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Yingyu Li
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Jiawen Wang
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Huiqing Ding
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Ningbo University, Ningbo, China
| | - Panfeng Fang
- Ningbo SinoCell Biotechnology Co., Ltd., Ningbo, China
| | - Yingzhi Huang
- Ningbo SinoCell Biotechnology Co., Ltd., Ningbo, China
| | - Jing Shi
- School of Pharmacy, Hangzhou Medical College, Hangzhou, China
| | - Jianqing Gao
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Tianyuan Zhang
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| |
Collapse
|
2
|
A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications. Stem Cell Rev Rep 2022; 18:2279-2295. [PMID: 35175538 PMCID: PMC8852915 DOI: 10.1007/s12015-022-10351-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2022] [Indexed: 12/22/2022]
Abstract
Background Allogeneic mesenchymal stromal cells (MSCs) have been used extensively in various clinical trials. Nevertheless, there are concerns about their efficacy, attributed mainly to the heterogeneity of the applied populations. Therefore, producing a consistent population of MSCs is crucial to improve their therapeutic efficacy. This study presents a good manufacturing practice (GMP)-compatible and cost-effective protocol for manufacturing, banking, and lot-release of a homogeneous population of human bone marrow-derived clonal MSCs (cMSCs). Methods Here, cMSCs were isolated based on the subfractionation culturing method. Afterward, isolated clones that could reproduce up to passage three were stored as the seed stock. To select proliferative clones, we used an innovative, cost-effective screening strategy based on lengthy serial passaging. Finally, the selected clones re-cultured from the seed stock to establish the following four-tired cell banking system: initial, master, working, and end of product cell banks (ICB, MCB, WCB, and EoPCB). Results Through a rigorous screening strategy, three clones were selected from a total of 21 clones that were stored during the clonal isolation process. The selected clones met the identity, quality, and safety assessments criteria. The validated clones were stored in the four-tiered cell bank system under GMP conditions, and certificates of analysis were provided for the three-individual ready-to-release batches. Finally, a stability study validated the EoPCB, release, and transport process of the frozen final products. Conclusion Collectively, this study presents a technical and translational overview of a GMP-compatible cMSCs manufacturing technology that could lead to the development of similar products for potential therapeutic applications. Graphical Abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1007/s12015-022-10351-x.
Collapse
|
3
|
Sion C, Ghannoum D, Ebel B, Gallo F, de Isla N, Guedon E, Chevalot I, Olmos E. A new perfusion mode of culture for WJ-MSCs expansion in a stirred and online monitored bioreactor. Biotechnol Bioeng 2021; 118:4453-4464. [PMID: 34387862 DOI: 10.1002/bit.27914] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 08/04/2021] [Accepted: 08/04/2021] [Indexed: 01/22/2023]
Abstract
As a clinical dose requires a minimum of 106 cells per kilogram of patients, it is, therefore, crucial to develop a scalable method of production of Wharton Jelly mesenchymal stem cells (WJ-MSCs) with maintained inner characteristics. Scalable expansion of WJ-MSCs on microcarriers usually found in cell culture, involves specific cell detachment using trypsin and could have harmful effects on cells. In this study, the performance of batch, fed-batch, and perfused-continuous mode of culture were compared. The batch and fed-batch modes resulted in expansion factors of 5 and 43, respectively. The perfused-continuous mode strategy consisted of the implementation of a settling tube inside the bioreactor. The diameter of the tube was calculated to maintain microcarriers colonized by cells in the bioreactor whereas empty microcarriers (responsible for potentially damaging collisions) were removed, using a continuous flow rate based on MSCs physiological requirements. Thanks to this strategy, a maximal number of 800 million cells was obtained in a 1.5 L bioreactor in 10 days. Lastly, online dielectric spectroscopy was implemented in the bioreactor and indicated that cell growth could be monitored during the culture.
Collapse
Affiliation(s)
- Caroline Sion
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| | - Dima Ghannoum
- Ingénierie Moléculaire et Physiopathologie Articulaire, Université de Lorraine, CNRS UMR 7365, Vandœuvre-lès-Nancy, France
| | - Bruno Ebel
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| | - Fanny Gallo
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| | - Natalia de Isla
- Ingénierie Moléculaire et Physiopathologie Articulaire, Université de Lorraine, CNRS UMR 7365, Vandœuvre-lès-Nancy, France
| | - Emmanuel Guedon
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| | - Isabelle Chevalot
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| | - Eric Olmos
- Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS UMR 7274, Vandoeuvre les Nancy, France
| |
Collapse
|
4
|
Van Beylen K, Youssef A, Peña Fernández A, Lambrechts T, Papantoniou I, Aerts JM. Lactate-Based Model Predictive Control Strategy of Cell Growth for Cell Therapy Applications. Bioengineering (Basel) 2020; 7:bioengineering7030078. [PMID: 32698462 PMCID: PMC7552707 DOI: 10.3390/bioengineering7030078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 07/15/2020] [Accepted: 07/15/2020] [Indexed: 12/24/2022] Open
Abstract
Implementing a personalised feeding strategy for each individual batch of a bioprocess could significantly reduce the unnecessary costs of overfeeding the cells. This paper uses lactate measurements during the cell culture process as an indication of cell growth to adapt the feeding strategy accordingly. For this purpose, a model predictive control is used to follow this a priori determined reference trajectory of cumulative lactate. Human progenitor cells from three different donors, which were cultivated in 12-well plates for five days using six different feeding strategies, are used as references. Each experimental set-up is performed in triplicate and for each run an individualised model-based predictive control (MPC) controller is developed. All process models exhibit an accuracy of 99.80% ± 0.02%, and all simulations to reproduce each experimental run, using the data as a reference trajectory, reached their target with a 98.64% ± 0.10% accuracy on average. This work represents a promising framework to control the cell growth through adapting the feeding strategy based on lactate measurements.
Collapse
Affiliation(s)
- Kathleen Van Beylen
- Department of Biosystems, Division Animal and Human Health Engineering, M3-BIORES: Measure, Model & Manage Bioresponses Laboratory, KU Leuven, Kasteelpark Arenberg 30, 3001 Heverlee, Belgium; (K.V.B.); (A.Y.); (A.P.F.); (T.L.)
- Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, Onderwijs en Navorsing 1, Herestraat 49, 3000 Leuven, Belgium;
| | - Ali Youssef
- Department of Biosystems, Division Animal and Human Health Engineering, M3-BIORES: Measure, Model & Manage Bioresponses Laboratory, KU Leuven, Kasteelpark Arenberg 30, 3001 Heverlee, Belgium; (K.V.B.); (A.Y.); (A.P.F.); (T.L.)
| | - Alberto Peña Fernández
- Department of Biosystems, Division Animal and Human Health Engineering, M3-BIORES: Measure, Model & Manage Bioresponses Laboratory, KU Leuven, Kasteelpark Arenberg 30, 3001 Heverlee, Belgium; (K.V.B.); (A.Y.); (A.P.F.); (T.L.)
| | - Toon Lambrechts
- Department of Biosystems, Division Animal and Human Health Engineering, M3-BIORES: Measure, Model & Manage Bioresponses Laboratory, KU Leuven, Kasteelpark Arenberg 30, 3001 Heverlee, Belgium; (K.V.B.); (A.Y.); (A.P.F.); (T.L.)
- Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, Onderwijs en Navorsing 1, Herestraat 49, 3000 Leuven, Belgium;
| | - Ioannis Papantoniou
- Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, Onderwijs en Navorsing 1, Herestraat 49, 3000 Leuven, Belgium;
- Skeletal Biology and Engineering Research Centre, Onderwijs en Navorsing 1, Herestraat 49, 3000 Leuven, Belgium
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology—Hellas (FORTH), 26504 Patras, Greece
| | - Jean-Marie Aerts
- Department of Biosystems, Division Animal and Human Health Engineering, M3-BIORES: Measure, Model & Manage Bioresponses Laboratory, KU Leuven, Kasteelpark Arenberg 30, 3001 Heverlee, Belgium; (K.V.B.); (A.Y.); (A.P.F.); (T.L.)
- Correspondence:
| |
Collapse
|
5
|
Costariol E, Rotondi M, Amini A, Hewitt CJ, Nienow AW, Heathman TRJ, Micheletti M, Rafiq QA. Establishing the scalable manufacture of primary human T-cells in an automated stirred-tank bioreactor. Biotechnol Bioeng 2019; 116:2488-2502. [PMID: 31184370 DOI: 10.1002/bit.27088] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Revised: 04/17/2019] [Accepted: 06/06/2019] [Indexed: 12/30/2022]
Abstract
Advanced cell and gene therapies such as chimeric antigen receptor T-cell immunotherapies (CAR-T), present a novel therapeutic modality for the treatment of acute and chronic conditions including acute lymphoblastic leukemia and non-Hodgkin lymphoma. However, the development of such immunotherapies requires the manufacture of large numbers of T-cells, which remains a major translational and commercial bottleneck due to the manual, small-scale, and often static culturing systems used for their production. Such systems are used because there is an unsubstantiated concern that primary T-cells are shear sensitive, or prefer static conditions, and therefore do not grow as effectively in more scalable, agitated systems, such as stirred-tank bioreactors, as compared with T-flasks and culture bags. In this study, we demonstrate that not only T-cells can be cultivated in an automated stirred-tank bioreactor system (ambr® 250), but that their growth is consistently and significantly better than that in T-flask static culture, with equivalent cell quality. Moreover, we demonstrate that at progressively higher agitation rates over the range studied here, and thereby, higher specific power inputs (P/M W kg-1 ), the higher the final viable T-cell density; that is, a cell density of 4.65 ± 0.24 × 106 viable cells ml-1 obtained at the highest P/M of 74 × 10-4 W kg-1 in comparison with 0.91 ± 0.07 × 106 viable cells ml-1 at the lowest P/M of 3.1 × 10-4 W kg-1 . We posit that this improvement is due to the inability at the lower agitation rates to effectively suspend the Dynabeads®, which are required to activate the T-cells; and that contact between them is improved at the higher agitation rates. Importantly, from the data obtained, there is no indication that T-cells prefer being grown under static conditions or are sensitive to fluid dynamic stresses within a stirred-tank bioreactor system at the agitation speeds investigated. Indeed, the opposite has proven to be the case, whereby, the cells grow better under higher agitation speeds while maintaining their quality. This study is the first demonstration of primary T-cell ex vivo manufacture activated by Dynabeads® in an automated stirred-tank bioreactor system such as the ambr® 250 and the findings have the potential to be applied to multiple other cell candidates for advanced therapy applications.
Collapse
Affiliation(s)
- Elena Costariol
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK
| | - Marco Rotondi
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK
| | - Arman Amini
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK
| | - Christopher J Hewitt
- School of Life and Health Sciences, Aston Medical Research Institute, Aston University, Birmingham, UK
| | - Alvin W Nienow
- School of Life and Health Sciences, Aston Medical Research Institute, Aston University, Birmingham, UK.,School of Chemical Engineering, University of Birmingham, Birmingham, UK
| | - Thomas R J Heathman
- Hitachi Chemical Advanced Therapeutics Solutions (HCATS), Allendale, New Jersey
| | - Martina Micheletti
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK
| | - Qasim A Rafiq
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, UK
| |
Collapse
|
6
|
Development of a process control strategy for the serum-free microcarrier expansion of human mesenchymal stem cells towards cost-effective and commercially viable manufacturing. Biochem Eng J 2019. [DOI: 10.1016/j.bej.2018.10.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
7
|
Trejo JL. Advances in the Ongoing Battle against the Consequences of Peripheral Nerve Injuries. Anat Rec (Hoboken) 2018; 301:1606-1613. [DOI: 10.1002/ar.23936] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Revised: 08/03/2018] [Accepted: 08/07/2018] [Indexed: 02/06/2023]
Affiliation(s)
- JosÉ L. Trejo
- Department of Translational Neuroscience; Cajal Institute, CSIC; Madrid Spain
| |
Collapse
|
8
|
Bahsoun S, Coopman K, Forsyth NR, Akam EC. The Role of Dissolved Oxygen Levels on Human Mesenchymal Stem Cell Culture Success, Regulatory Compliance, and Therapeutic Potential. Stem Cells Dev 2018; 27:1303-1321. [DOI: 10.1089/scd.2017.0291] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Soukaina Bahsoun
- School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom
| | - Karen Coopman
- Centre for Biological Engineering, Loughborough University, Loughborough, United Kingdom
| | - Nicholas R. Forsyth
- Guy Hilton Research Centre, Institute for Science and Technology in Medicine, Keele University, Keele, United Kingdom
| | - Elizabeth C. Akam
- School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom
| |
Collapse
|
9
|
Heathman TR, Nienow AW, Rafiq QA, Coopman K, Kara B, Hewitt CJ. Agitation and aeration of stirred-bioreactors for the microcarrier culture of human mesenchymal stem cells and potential implications for large-scale bioprocess development. Biochem Eng J 2018. [DOI: 10.1016/j.bej.2018.04.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
10
|
Rafiq QA, Ruck S, Hanga MP, Heathman TR, Coopman K, Nienow AW, Williams DJ, Hewitt CJ. Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: Utilising the phenomenon to improve culture performance. Biochem Eng J 2018. [DOI: 10.1016/j.bej.2017.11.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Budhiraja G, Sahu N, Subramanian A. Low-Intensity Ultrasound Upregulates the Expression of Cyclin-D1 and Promotes Cellular Proliferation in Human Mesenchymal Stem Cells. Biotechnol J 2018; 13:e1700382. [PMID: 29283212 DOI: 10.1002/biot.201700382] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 12/07/2017] [Indexed: 11/09/2022]
Abstract
Human mesenchymal stem cells (hMSCs) hold great potential for cellular based therapeutics and tissue engineering applications and their expansion is an interesting prospect due to their low availability from in vivo sources. Therefore, this study investigated the effect of continuous-wave low-intensity ultrasound (LIUS) at 5.0-MHz and 14.0-kPa (<20 mW cm-2 ) on the proliferative capacity, colony-formation efficiency, genetic stability, and differentiation potential of hMSCs. Additionally, potential signaling pathways involved in LIUS-mediated proliferation of hMSCs are studied. Compared to non-stimulated controls, LIUS-treated hMSCs shows a 1.9-fold greater colony-forming efficiency and 2.5-fold higher rate of cell proliferation, respectively. Differential staining and qRT-PCR analysis for selective chondrogenic, osteogenic, and adipogenic markers further confirmed that the LIUS treatment did not impact the multipotency of hMSCs. LIUS-treated hMSCs expressed normal male karyotype. The synthesis of cyclin-D1, a master regulator of cellular proliferation, is upregulated under LIUS and its enhanced mRNA expression under LIUS is noted to be mediated by the activation of both MAPK/ERK and PI3K/AKT pathways. In conclusion, LIUS promotes proliferation and self-renewal capacity of hMSCs.
Collapse
Affiliation(s)
- Gaurav Budhiraja
- Department of Chemical and Biomolecular Engineering University of Nebraska-Lincoln, Lincoln, NE, 68588-0643, USA
| | - Neety Sahu
- Department of Chemical and Biomolecular Engineering University of Nebraska-Lincoln, Lincoln, NE, 68588-0643, USA
| | - Anuradha Subramanian
- Department of Chemical and Biomolecular Engineering University of Nebraska-Lincoln, Lincoln, NE, 68588-0643, USA
| |
Collapse
|
12
|
Rafiq QA, Hanga MP, Heathman TRJ, Coopman K, Nienow AW, Williams DJ, Hewitt CJ. Process development of human multipotent stromal cell microcarrier culture using an automated high-throughput microbioreactor. Biotechnol Bioeng 2017. [PMID: 28627713 PMCID: PMC5615370 DOI: 10.1002/bit.26359] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Microbioreactors play a critical role in process development as they reduce reagent requirements and can facilitate high-throughput screening of process parameters and culture conditions. Here, we have demonstrated and explained in detail, for the first time, the amenability of the automated ambr15 cell culture microbioreactor system for the development of scalable adherent human mesenchymal multipotent stromal/stem cell (hMSC) microcarrier culture processes. This was achieved by first improving suspension and mixing of the microcarriers and then improving cell attachment thereby reducing the initial growth lag phase. The latter was achieved by using only 50% of the final working volume of medium for the first 24 h and using an intermittent agitation strategy. These changes resulted in >150% increase in viable cell density after 24 h compared to the original process (no agitation for 24 h and 100% working volume). Using the same methodology as in the ambr15, similar improvements were obtained with larger scale spinner flask studies. Finally, this improved bioprocess methodology based on a serum-based medium was applied to a serum-free process in the ambr15, resulting in >250% increase in yield compared to the serum-based process. At both scales, the agitation used during culture was the minimum required for microcarrier suspension, NJS . The use of the ambr15, with its improved control compared to the spinner flask, reduced the coefficient of variation on viable cell density in the serum containing medium from 7.65% to 4.08%, and the switch to serum free further reduced these to 1.06-0.54%, respectively. The combination of both serum-free and automated processing improved the reproducibility more than 10-fold compared to the serum-based, manual spinner flask process. The findings of this study demonstrate that the ambr15 microbioreactor is an effective tool for bioprocess development of hMSC microcarrier cultures and that a combination of serum-free medium, control, and automation improves both process yield and consistency. Biotechnol. Bioeng. 2017;114: 2253-2266. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Qasim A Rafiq
- Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, Gower Street, London, United Kingdom.,Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.,Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom
| | - Mariana P Hanga
- Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.,Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom
| | - Thomas R J Heathman
- Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom.,PCT, A Hitachi Group Company, Allendale, New Jersey
| | - Karen Coopman
- Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom
| | - Alvin W Nienow
- Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.,Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom.,School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, United Kingdom
| | - David J Williams
- Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom
| | - Christopher J Hewitt
- Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, United Kingdom.,Centre for Biological Engineering, Loughborough University, Leicestershire LE11 3TU, United Kingdom
| |
Collapse
|
13
|
Heathman TR, Rafiq QA, Chan AK, Coopman K, Nienow AW, Kara B, Hewitt CJ. Characterization of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. Biochem Eng J 2016. [DOI: 10.1016/j.bej.2015.06.018] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
14
|
Rafiq QA, Coopman K, Nienow AW, Hewitt CJ. Systematic microcarrier screening and agitated culture conditions improves human mesenchymal stem cell yield in bioreactors. Biotechnol J 2016; 11:473-86. [PMID: 26632496 PMCID: PMC4991290 DOI: 10.1002/biot.201400862] [Citation(s) in RCA: 103] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Revised: 07/07/2015] [Accepted: 11/30/2015] [Indexed: 12/23/2022]
Abstract
Production of human mesenchymal stem cells for allogeneic cell therapies requires scalable, cost-effective manufacturing processes. Microcarriers enable the culture of anchorage-dependent cells in stirred-tank bioreactors. However, no robust, transferable methodology for microcarrier selection exists, with studies providing little or no reason explaining why a microcarrier was employed. We systematically evaluated 13 microcarriers for human bone marrow-derived MSC (hBM-MSCs) expansion from three donors to establish a reproducible and transferable methodology for microcarrier selection. Monolayer studies demonstrated input cell line variability with respect to growth kinetics and metabolite flux. HBM-MSC1 underwent more cumulative population doublings over three passages in comparison to hBM-MSC2 and hBM-MSC3. In 100 mL spinner flasks, agitated conditions were significantly better than static conditions, irrespective of donor, and relative microcarrier performance was identical where the same microcarriers outperformed others with respect to growth kinetics and metabolite flux. Relative growth kinetics between donor cells on the microcarriers were the same as the monolayer study. Plastic microcarriers were selected as the optimal microcarrier for hBM-MSC expansion. HBM-MSCs were successfully harvested and characterised, demonstrating hBM-MSC immunophenotype and differentiation capacity. This approach provides a systematic method for microcarrier selection, and the findings identify potentially significant bioprocessing implications for microcarrier-based allogeneic cell therapy manufacture.
Collapse
Affiliation(s)
- Qasim A Rafiq
- Centre for Biological Engineering, Department of Chemical Engineering, Loughborough University, Leicestershire, United Kingdom.,Wolfson School of Manufacturing and Mechanical Engineering, Loughborough University, Leicestershire, United Kingdom.,Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, United Kingdom
| | - Karen Coopman
- Centre for Biological Engineering, Department of Chemical Engineering, Loughborough University, Leicestershire, United Kingdom
| | - Alvin W Nienow
- Centre for Biological Engineering, Department of Chemical Engineering, Loughborough University, Leicestershire, United Kingdom.,School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, United Kingdom
| | - Christopher J Hewitt
- Centre for Biological Engineering, Department of Chemical Engineering, Loughborough University, Leicestershire, United Kingdom. .,Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, United Kingdom.
| |
Collapse
|
15
|
|
16
|
Prowse AB, Timmins NE, Yau TM, Li RK, Weisel RD, Keller G, Zandstra PW. Transforming the Promise of Pluripotent Stem Cell-Derived Cardiomyocytes to a Therapy: Challenges and Solutions for Clinical Trials. Can J Cardiol 2014; 30:1335-49. [DOI: 10.1016/j.cjca.2014.08.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Revised: 08/06/2014] [Accepted: 08/11/2014] [Indexed: 01/08/2023] Open
|
17
|
Ogle BM, Palecek SP. Editorial: stem cell engineering - discovery, diagnostics and therapies. Biotechnol J 2013; 8:390-1. [PMID: 23554245 DOI: 10.1002/biot.201300114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Stem cell engineering - discovery, diagnostics and therapies: This Special Issue is edited by Brenda Ogle and Sean Palecek and is based on presentations from the Third International Conference on Stem Cell Engineering, co-sponsored by the Society of Biological Engineering and the International Society for Stem Cell Research, held in Seattle, WA from April 29-May 2, 2012.
Collapse
Affiliation(s)
- Brenda M Ogle
- Department of Biomedical Engineering, College of Engineering, University of Wisconsin-Madison, WI, USA
| | | |
Collapse
|
18
|
Rafiq QA, Brosnan KM, Coopman K, Nienow AW, Hewitt CJ. Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol Lett 2013; 35:1233-45. [PMID: 23609232 DOI: 10.1007/s10529-013-1211-9] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Accepted: 04/05/2013] [Indexed: 10/26/2022]
Abstract
For the first time, fully functional human mesenchymal stem cells (hMSCs) have been cultured at the litre-scale on microcarriers in a stirred-tank 5 l bioreactor, (2.5 l working volume) and were harvested via a potentially scalable detachment protocol that allowed for the successful detachment of hMSCs from the cell-microcarrier suspension. Over 12 days, the dissolved O2 concentration was >45 % of saturation and the pH between 7.2 and 6.7 giving a maximum cell density in the 5 l bioreactor of 1.7 × 10(5) cells/ml; this represents >sixfold expansion of the hMSCs, equivalent to that achievable from 65 fully-confluent T-175 flasks. During this time, the average specific O2 uptake of the cells in the 5 l bioreactor was 8.1 fmol/cell h and, in all cases, the 5 l bioreactors outperformed the equivalent 100 ml spinner-flasks run in parallel with respect to cell yields and growth rates. In addition, yield coefficients, specific growth rates and doubling times were calculated for all systems. Neither the upstream nor downstream bioprocessing unit operations had a discernible effect on cell quality with the harvested cells retaining their immunophenotypic markers, key morphological features and differentiation capacity.
Collapse
Affiliation(s)
- Qasim A Rafiq
- Department of Chemical Engineering, Centre for Biological Engineering, Loughborough University, Leicestershire, LE11 3TU, UK
| | | | | | | | | |
Collapse
|